Symeres acquires DGr Pharma

CRDMO Symeres is to acquire its Netherlands-based DGr Pharma, a drug development-focused consultancy in the US, in order to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma. This is supported by private equity firm Keensight Capital.

DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy in early drug development, notably antibodies, ADCs and oligonucleotides. Core services include chemical-pharmaceutical, non-clinical and clinical development planning, QA and regulatory submissions, and GCP- and GLP-accredited pharmacokinetic data analysis services.

Symeres, which already has sites in the Netherlands, the Czech Republic, Finland and the US, said that DGr Pharma “adds significant regulatory depth to the Symeres portfolio enabling it to deliver a more integrated solution across the full spectrum of drug discovery and development”.